文献速递其他结缔组织病

抗核抗体阴性系统性硬化症患者中存在抗真核起始因子2B、抗RuvBL1/2和抗合成酶抗体

Presence of anti-eukaryotic initiation factor-2B, anti-RuvBL1/2 and anti-synthetase antibodies in patients with anti-nuclear antibody negative systemic sclerosis.
PubMed 文献 · Rheumatology (Oxford) · 2018-01-01

研究对来自大型代表性系统性硬化症(SSc)队列的128份抗核抗体(ANA)阴性血清进行免疫沉淀,检测抗真核起始因子2B(anti-eIF2B)等细胞质自身抗体。抗eIF2B抗体见于9例(7%),其中8例为弥漫性皮肤型SSc,7例有SSc相关间质性肺病(SSc-ILD);抗合成酶抗体见于7例(5.5%),均符合2013年ACR/EULAR分类标准并有SSc-ILD证据;抗RuvBL1/2抗体见于2例重叠综合征患者。

要点

  • ANA阴性SSc血清中抗eIF2B抗体占7%(9/128),多数为dcSSc且合并SSc-ILD。
  • 抗合成酶抗体占5.5%(7/128),均符合2013年ACR/EULAR分类标准并有SSc-ILD证据。
  • 抗RuvBL1/2抗体见于2例SSc重叠综合征患者。

核心结论

  • 抗eIF2B抗体是ANA阴性血清中与dcSSc和SSc-ILD强临床关联的SSc特异性细胞质自身抗体。
  • 抗合成酶抗体及抗RuvBL1/2等其他新发现的SSc特异性抗体也可在ANA阴性SSc中检出。

研究设计与样本

  • 对来自硬皮病家族登记与DNA库的ANA阴性血清行间接免疫荧光和放射性标记蛋白免疫沉淀(±免疫清除)以鉴定抗eIF2B及其他结缔组织病相关自身抗体。
  • 共对128份ANA阴性样本行免疫沉淀,样本来自3249例SSc患者。
  • 对阳性样本的临床表型进行评估。

主要发现

  • 抗eIF2B抗体见于9例患者(7%),其中8/9为dcSSc;有胸部影像可用的抗eIF2B患者全部(7/9)存在SSc-ILD。
  • 抗合成酶抗体(靶向PL12、PL7、OJ和Zo)见于7例患者(5.5%),均符合2013年ACR/EULAR的SSc分类标准,在相关结局可评估者中均有SSc-ILD证据。
  • 抗RuvBL1/2抗体见于2例SSc重叠综合征患者。

关键数值与推荐

  • 抗eIF2B抗体在128份ANA阴性样本中检出9例(7%),其中dcSSc 8/9,有胸部影像者SSc-ILD 7/9。
  • 抗合成酶抗体在128份样本中检出7例(5.5%),均符合2013年ACR/EULAR分类标准。
  • 抗RuvBL1/2抗体在128份样本中检出2例,均为SSc重叠综合征。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Autoantibodies targeting ubiquitously expressed nuclear antigens can be identified in most patients with SSc. Cytoplasmic autoantibodies (in otherwise ANA-negative sera) targeting eukaryotic initiation factor-2B (anti-eIF2B) have recently been identified in SSc with clinical associations to dcSSc disease and interstitial lung disease (ILD), although the majority of samples originated from a tertiary SSc-ILD centre. We investigated the prevalence and clinical associations of recently described SSc-specific (including anti-eIF2B) and other cytoplasmic autoantibodies in ANA-negative sera obtained from a large representative SSc cohort. METHODS: ANA-negative sera from the Scleroderma Family Registry and DNA Repository underwent indirect immunofluorescence, radiolabelled protein immunoprecipitation (± immunodepletion) to identify anti-eIF2B and other CTD-related autoantibodies. The clinical phenotype of positive samples was evaluated. RESULTS: Immunoprecipitation was performed on 128 ANA-negative samples (obtained from 3249 SSc patients). Anti-eIF2B antibodies were present in nine patients (7%), the majority of whom had dcSSc (8/9). SSc-ILD was present in all anti-eIF2B patients for whom chest imaging was available (7/9). Anti-synthetase autoantibodies (targeting PL12, PL7, OJ and Zo) were identified in seven patients (5.5%), all of whom fulfilled the 2013 ACR/EULAR classification criteria for SSc and had evidence of SSc-ILD where relevant outcomes were available for evaluation. Anti-RuvBL1/2 antibodies were identified in two patients with SSc-overlap syndromes. CONCLUSION: Anti-eIF2B antibodies are cytoplasmic SSc-specific autoantibodies with strong clinical associations with dcSSc and SSc-ILD found in ANA-negative sera. Anti-synthetase autoantibodies, and other recently discovered SSc-specific antibodies such as anti-RuvBL1/2, can also be identified in ANA-negative SSc.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Pauling JD, Salazar G, Lu H, et al. Presence of anti-eukaryotic initiation factor-2B, anti-RuvBL1/2 and anti-synthetase antibodies in patients with anti-nuclear antibody negative systemic sclerosis. Rheumatology (Oxford). 2018. PMID: 29294089. doi:10.1093/rheumatology/kex458

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。